What’s next for FDA? Four areas where the agency will have to fill a Gottlieb-sized void
What’s waiting on the desk of the next FDA commissioner.
Regulatory
Reports: Purdue weighs Chapter 11
The drugmaker is facing thousands of lawsuits saying the company contributed to the opioid crisis.
Expect legislative baby steps, not big leaps on drug prices
Even though both parties agree on lowering drug prices, experts predict changes will be incremental.
4 takeaways from Tuesday’s Senate drug pricing hearing
Seven pharma executives were grilled on drug prices on Capitol Hill on Tuesday.
Live blog: Pharma execs on the Hill
The latest from the Senate Finance Committee’s grilling of pharma executives on Capitol Hill.
What to watch: Congress to grill pharma CEOs over drug prices Tuesday
Seven top pharma executives are set to testify in front of lawmakers.
Was President Trump’s plan to reduce drug prices DOA?
President Trump’s blueprint to lower drug prices hasn’t made it out of the brainstorm phase.
Texas ACA ruling could reverberate across healthcare
Texas Judge Reed O’Connor’s ruling on the ACA could affect both insurers and pharma.
Democrats could make drug pricing deal with President Trump
Many midterm winners campaigned on bringing down prices, and experts predict the issue to remain top of mind.
How the pharma industry may be impacted by drug pricing and other policies in 2019
Now that the political climate lends itself to action on drug pricing, the days of pharma nirvana may be coming to an end. Here’s a look at the policy considerations likely to vex the industry in the year ahead.
Want to read more?
Please login or register first to view this content.
